Periodic Reporting for period 1 - Tumor-Treg-Targeting (Training Network for the education of the next generation scientist in targeting the supressive capacity of regulatory T-cells specifically within tumours)
Reporting period: 2018-06-01 to 2020-05-31
Objective 1: to develop novel biologicals that can target cell populations - such as cancerous cells or specific subtypes of leukocytes - with unprecedented specificity.
Objective 2: to specifically engage particular cell types of the innate immune system within tumours with applied biologicals in a directed fashion.
Objective 3: to target known immune-modulating cytokines or known check-point inhibitors directly into established tumours.
1) A novel efficient bispecific antibody format, combining a conventional antigen-binding fragment with a single domain antibody, avoids potential heavy-light chain mis-pairing. Huang S, Segués A, Hulsik DL, Zaiss DM, Sijts AJAM, van Duijnhoven SMJ, van Elsas A. J Immunol Methods. 2020 Aug;483:112811. doi: 10.1016/j.jim.2020.112811. Epub 2020 Jun 19.
2) Bispecific antibodies targeting dual tumor-associated antigens in cancer therapy. Huang S, van Duijnhoven SMJ, Sijts AJAM, van Elsas A. J Cancer Res Clin Oncol. 2020 Dec;146(12):3111-3122. doi: 10.1007/s00432-020-03404-6. Epub 2020 Sep 28.
3) Isotype selection for antibody-based cancer therapy. Vukovic N, van Elsas A, Verbeek JS, Zaiss DMW. Clin Exp Immunol. 2021 Mar;203(3):351-365. doi: 10.1111/cei.13545. Epub 2020 Nov 30.
4) Purification of murine immunoglobulin E (IgE) by thiophilic interaction chromatography (TIC). Vukovic N, Harraou S, van Duijnhoven SMJ, Zaiss DM, van Elsas A. J Immunol Methods. 2021 Feb;489:112914. doi: 10.1016/j.jim.2020.112914. Epub 2020 Nov 14.